niacinamide has been researched along with B-Cell Lymphoma in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma." | 3.83 | Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. ( Barassi, C; Bernasconi, E; Bertoni, F; Cascione, L; Gaudio, E; Goodstal, S; Kwee, I; Ponzoni, M; Rinaldi, A; Stathis, A; Tarantelli, C; Targa, A; Zucca, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tarantelli, C | 2 |
| Zhang, L | 1 |
| Curti, E | 1 |
| Gaudio, E | 2 |
| Spriano, F | 1 |
| Priebe, V | 1 |
| Cascione, L | 2 |
| Arribas, AJ | 1 |
| Zucca, E | 2 |
| Rossi, D | 1 |
| Stathis, A | 2 |
| Bertoni, F | 2 |
| Kwee, I | 1 |
| Barassi, C | 1 |
| Bernasconi, E | 1 |
| Rinaldi, A | 1 |
| Ponzoni, M | 1 |
| Targa, A | 1 |
| Goodstal, S | 1 |
2 other studies available for niacinamide and B-Cell Lymphoma
| Article | Year |
|---|---|
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge | 2019 |
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Class I Phosphatidylinosito | 2016 |